

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 1 of 9
Print date: 27/01/2025

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING.

1.1 Product identifier.

Product Name: MAXURETHANE INJECTION CONSOLIDATED CB
UFI: 2HC1-E0XJ-Q00T-822S

1.2 Relevant identified uses of the substance or mixture and uses advised against.

Injection System

Uses advised against:

Uses other than those recommended.

1.3 Details of the supplier of the safety data sheet.

Company: **DRIZORO SAU**
Address: C/ Primavera, 50 - 52 Parque Industrial Las Monjas
City: 28850 - Torrejón de Ardoz
Province: Madrid (Spain)
Telephone: +34 91 676 66 76
Fax: +34 91 675 11 31
E-mail: info@drizoro.com
Web: www.drizoro.com

1.4 Emergency telephone number: +34 91 676 66 76 (Only available during office hours; Monday-Friday; 08:00-18:00)

SECTION 2: HAZARDS IDENTIFICATION.

2.1 Classification of the substance or mixture.

In accordance with Regulation (EC) No 1272/2008:

Carc. 2 : Suspected of causing cancer.

Eye Irrit. 2 : Causes serious eye irritation.

Resp. Sens. 1 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.

STOT RE 2 : May cause damage to organs through prolonged or repeated exposure.

STOT SE 3 : May cause respiratory irritation.

Skin Irrit. 2 : Causes skin irritation.

2.2 Label elements.

Labelling in accordance with Regulation (EC) No 1272/2008:

Pictograms:



Signal Word:

Danger

Hazard statements:

H315 Causes skin irritation.

H319 Causes serious eye irritation.

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

H335 May cause respiratory irritation.

H351 Suspected of causing cancer.

H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements:

-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB



Version 1 Date of compilation: 27/01/2025

Page 2 of 9
Print date: 27/01/2025

P201	Obtain special instructions before use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P280	Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P284	[In case of inadequate ventilation] wear respiratory protection.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P342+P311	If experiencing respiratory symptoms: Call a POISON CENTER/doctor/...
P403+P233	Store in a well-ventilated place. Keep container tightly closed.

Contains:
Polymeric diphenylmethane diisocyanate

2.3 Other hazards.

The mixture does not contain substances classified as PBT.
The mixture does not contain substances classified as vPvB.
The mixture does not contain any endocrine disrupting properties substances.

In normal use conditions and in its original form, the product itself does not involve any other risk for health and the environment.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS.

3.1 Substances.

Not applicable.

3.2 Mixtures.

Substances posing a danger to health or the environment in accordance with the Regulation (EC) No. 1272/2008, assigned a Community exposure limit in the workplace, and classified as PBT/vPvB or included in the Candidate List:

Identifiers	Name	Concentrate	(*)Classification - Regulation (EC) No 1272/2008	
			Classification	Specifics concentration limits and Acute toxicity estimate
CAS No: 9016-87-9	[1] Polymeric diphenylmethane diisocyanate	20 - 100 %	Carc. 2, H351 - Eye Irrit. 2, H319 - Resp. Sens. 1, H334 - STOT RE 2, H373 - STOT SE 3, H335 - Skin Irrit. 2, H315	-

(*) The complete text of the H phrases is given in section 16 of this Safety Data Sheet.

[1] Substance with a European Union exposure limit in the workplace (see section 8.1).

SECTION 4: FIRST AID MEASURES.

IRRITANT MIXTURE. Its repeated or prolonged contact with the skin or mucous membranes can cause irritant symptoms such as reddening of the skin, blisters, or dermatitis. Some of the symptoms may not be immediate. They can cause allergic reactions on the skin.

4.1 Description of first aid measures.

In case of doubt or when symptoms of feeling unwell persist, get medical attention. Never administer anything orally to persons who are unconscious.

Inhalation.

Take the victim into open air; keep them warm and calm. If breathing is irregular or stops, perform artificial respiration. Do not administer anything orally. If unconscious, place them in a suitable position and seek medical assistance.

Eye contact.

Remove contact lenses, if present and if it is easy to do. Wash eyes with plenty of clean and cool water for at least 10 minutes while pulling eyelids up, and seek medical assistance. Don't let the person to rub the affected eye.

Skin contact.

-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 3 of 9
Print date: 27/01/2025

Remove contaminated clothing. Wash skin vigorously with water and soap or a suitable skin cleaner. NEVER use solvents or thinners.

Ingestion.

If accidentally ingested, seek immediate medical attention. Keep calm. NEVER induce vomiting.

4.2 Most important symptoms and effects, both acute and delayed.

Irritant Product, repeated or prolonged contact with skin or mucous membranes can cause redness, blisters or dermatitis, inhalation of spray mist or particles in suspension may cause irritation of the respiratory tract, some symptoms may not be immediate.

Repeated or prolonged eye contact may cause stinging, tearing, redness, swelling, and blurred vision.

Long-term chronic exposure may result in injury to certain organs or tissues.

It may cause an allergic reaction in the respiratory system. Chronic exposure can lead to asthma.

4.3 Indication of any immediate medical attention and special treatment needed.

In case of doubt or when symptoms of feeling unwell persist, get medical attention. Never administer anything orally to persons who are unconscious. Keep the person comfortable. Turn him/her over to the left side and stay there while waiting for medical care.

SECTION 5: FIREFIGHTING MEASURES.

The product is NOT classified as flammable, in case of fire the following measures should be taken:

5.1 Extinguishing media.

Suitable extinguishing media:

Extinguisher powder or CO₂. In case of more serious fires, also alcohol-resistant foam and water spray.

Unsuitable extinguishing media:

Do not use a direct stream of water to extinguish. In the presence of electrical voltage, you cannot use water or foam as extinguishing media.

5.2 Special hazards arising from the substance or mixture.

Special risks.

Exposure to combustion or decomposition products can be harmful to your health.

5.3 Advice for firefighters.

Use water to cool tanks, cisterns, or containers close to the heat source or fire. Take wind direction into account. Prevent the products used to fight the fire from going into drains, sewers, or waterways.

Fire protection equipment.

According to the size of the fire, it may be necessary to use protective suits against the heat, individual breathing equipment, gloves, protective goggles or facemasks, and boots.

SECTION 6: ACCIDENTAL RELEASE MEASURES.

6.1 Personal precautions, protective equipment and emergency procedures.

For exposure control and individual protection measures, see section 8.

6.2 Environmental precautions.

Product not classified as hazardous for the environment, avoid spillage as much as possible.

6.3 Methods and material for containment and cleaning up.

Contain and collect spillage with inert absorbent material (earth, sand, vermiculite, Kieselguhr...) and clean the area immediately with a suitable decontaminant.

Deposit waste in closed and suitable containers for disposal, in compliance with local and national regulations (see section 13).

6.4 Reference to other sections.

For exposure control and individual protection measures, see section 8.

For later elimination of waste, follow the recommendations under section 13.

-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 4 of 9
Print date: 27/01/2025

SECTION 7: HANDLING AND STORAGE.

7.1 Precautions for safe handling.

For personal protection, see section 8.

In the application area, smoking, eating, and drinking must be prohibited.

Follow legislation on occupational health and safety.

Never use pressure to empty the containers. They are not pressure-resistant containers. Keep the product in containers made of a material identical to the original.

7.2 Conditions for safe storage, including any incompatibilities.

Store according to local legislation. Observe indications on the label. Store the containers between 5 and 25 ° C, in a dry and well-ventilated place, far from sources of heat and direct solar light. Keep far away from ignition points. Keep away from oxidising agents and from highly acidic or alkaline materials. Do not smoke. Prevent the entry of non-authorised persons. Once the containers are open, they must be carefully closed and placed vertically to prevent spills.

The product is not affected by Directive 2012/18/EU (SEVESO III).

7.3 Specific end use(s).

Not available.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION.

8.1 Control parameters.

Work exposure limit for:

Name	CAS No.	Country	Limit value	ppm	mg/m ³
Polymeric diphenylmethane diisocyanate	9016-87-9	European Union [1]	Eight hours		0,06 (Calculated as NCO, skin dermal and respiratory sensitization)
			Short term		0,012 (Calculated as NCO, skin dermal and respiratory sensitization)

[1] According both Binding Occupational Exposure Limits (BOELVs) and Indicative Occupational Exposure Limits (IOELVs) adopted by Scientific Committee for Occupational Exposure Limits to Chemical Agents (SCOEL).

The product does NOT contain substances with Biological Limit Values.

8.2 Exposure controls.

Measures of a technical nature:

Provide adequate ventilation, which can be achieved by using good local exhaust-ventilation and a good general exhaust system.

Concentration:	100 %
Uses:	Injection System
Breathing protection:	
If the recommended technical measures are observed, no individual protection equipment is necessary.	
Hand protection:	
PPE:	Protective gloves against chemicals.
Characteristics:	«CE» marking, category III.
CEN standards:	EN 374-1, En 374-2, EN 374-3, EN 420
Maintenance:	Keep in a dry place, away from any sources of heat, and avoid exposure to sunlight as much as possible. Do not make any changes to the gloves that may alter their resistance, or apply paints, solvents or adhesives.
Observations:	Gloves should be of the appropriate size and fit the user's hand well, not being too loose or too tight. Always use with clean, dry hands.



-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 5 of 9
Print date: 27/01/2025

Material:	PVC (polyvinyl chloride)	Breakthrough time (min.):	> 480	Material thickness (mm):	0,35
Eye protection:					
PPE:	Protective goggles with built-in frame.				
Characteristics:	«CE» marking, category II. Eye protector with built-in frame for protection against dust, smoke, fog and vapour.				
CEN standards:	EN 165, EN 166, EN 167, EN 168				
Maintenance:	Visibility through lenses should be ideal. Therefore, these parts should be cleaned daily. Protectors should be disinfected periodically following the manufacturer's instructions.				
Observations:	Some signs of wear and tear include: yellow colouring of the lenses, superficial scratching of the lenses, scraping etc.				
Skin protection:					
PPE:	Chemical protective clothing				
Characteristics:	«CE» marking, category III. Clothing should fit properly. The level of protection must be set according to a test parameter called BT (Breakthrough Time), which indicates how long it takes for the chemical to pass through the material.				
CEN standards:	EN 464, EN 340, EN 943-1, EN 943-2, EN ISO 6529, EN ISO 6530, EN 13034				
Maintenance:	In order to guarantee uniform protection, follow the washing and maintenance instructions provided by the manufacturer.				
Observations:	The protective clothing's design should facilitate correct positioning, staying in place without moving for the period of use expected, bearing in mind environmental factors as well as any movement or position the user might adopt while carrying out the activity.				
PPE:	Work footwear.				
Characteristics:	«CE» marking, category II.				
CEN standards:	EN ISO 13287, EN 20347				
Maintenance:	This product adapts to the first user's foot shape. That is why, as well as for hygienic reasons, it should not be used by other people.				
Observations:	Work footwear for professional use includes protection elements aimed at protecting users against any injury resulting from an accident				

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES.

9.1 Information on basic physical and chemical properties.

Physical state: Liquid

Colour: Marrón oscuro

Odour: Not applicable/Not available due to the nature/properties of the product

Odour threshold: Not applicable

Melting point: Not available

Freezing point: Not available

Boiling point or initial boiling point and boiling range: >300 °C

Flammability: Not applicable

Lower explosion limit: Not applicable

Upper explosion limit: Not applicable (Not relevant for this type of product)

Flash point: Not available

Auto-ignition temperature: Not applicable

Decomposition temperature: Not applicable (Not relevant for this type of product)

pH: Not applicable (Substance/mixture is non-soluble (in water)).

Kinematic viscosity: Not available

Solubility: Not available

Hydrosolubility: Not applicable

Liposolubility: Not applicable (Not relevant for this type of product)

Partition coefficient n-octanol/water (log value): Not applicable

Vapour pressure: Not applicable

Absolute density: Not applicable

Relative density: 1.22

Relative vapour density: Not applicable

Particle characteristics: Not applicable

9.2 Other information

Not applicable/Not available due to the nature/properties of the product

-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 6 of 9
Print date: 27/01/2025

SECTION 10: STABILITY AND REACTIVITY.

10.1 Reactivity.

The product does not present hazards by their reactivity.

10.2 Chemical stability.

Stable under the recommended handling and storage conditions (see section 7).

10.3 Possibility of hazardous reactions.

The product does not present possibility of hazardous reactions.

10.4 Conditions to avoid.

Avoid any improper handling.

10.5 Incompatible materials.

Keep away from oxidising agents and from highly alkaline or acidic materials in order to prevent exothermic reactions.

10.6 Hazardous decomposition products.

No decomposition if used for the intended uses.

SECTION 11: TOXICOLOGICAL INFORMATION.

IRRITANT MIXTURE. Splashes in the eyes can cause irritation.

IRRITANT MIXTURE. The inhalation of spray mist or suspended particulates can irritate the respiratory tract. It can also cause serious respiratory difficulties, central nervous system disorders, and in extreme cases, unconsciousness.

IRRITANT MIXTURE. Its repeated or prolonged contact with the skin or mucous membranes can cause irritant symptoms such as reddening of the skin, blisters, or dermatitis. Some of the symptoms may not be immediate. They can cause allergic reactions on the skin.

11.1 Information on hazard classes as defined in Regulation (EC) N° 1272/2008.

There are no tested data available on the product.

Repeated or prolonged contact with the product can cause the elimination of oil from the skin, giving rise to non-allergic contact dermatitis and absorption of the product through the skin.

Repeated or prolonged eye contact may cause stinging, tearing, redness, swelling, and blurred vision.

a) acute toxicity;

Not conclusive data for classification.

b) skin corrosion/irritation;

Product classified:

Skin irritant, Category 2: Causes skin irritation.

c) serious eye damage/irritation;

Product classified:

Eye irritation, Category 2: Causes serious eye irritation.

d) respiratory or skin sensitisation;

Product classified:

Respiratory sensitiser, Category 1: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

e) germ cell mutagenicity;

Not conclusive data for classification.

f) carcinogenicity;

Product classified:

Carcinogen, Category 2: Suspected of causing cancer.

g) reproductive toxicity;

Not conclusive data for classification.

h) STOT-single exposure;

Product classified:

Specific target organ toxicity following a single exposure, Category 3: May cause respiratory irritation.

-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 7 of 9
Print date: 27/01/2025

i) STOT-repeated exposure;

Product classified:

Specific target organ toxicity following a repeated exposure, Category 2: May cause damage to organs through prolonged or repeated exposure.

j) aspiration hazard;

Not conclusive data for classification.

11.2 Information on other hazards.

Endocrine disrupting properties

This product does not contain components with endocrine-disrupting properties with effects on human health.

Other information

There is no information available on other adverse health effects.

SECTION 12: ECOLOGICAL INFORMATION.

12.1 Toxicity.

No information is available regarding the ecotoxicity of the substances present.

12.2 Persistence and degradability.

No information is available regarding the biodegradability of the substances present.

No information is available on the degradability of the substances present.

No information is available about persistence and degradability of the product.

12.3 Bioaccumulative potential.

No information is available regarding the bioaccumulation of the substances present.

12.4 Mobility in soil.

No information is available about the mobility in soil.

The product must not be allowed to go into sewers or waterways.

Prevent penetration into the ground.

12.5 Results of PBT and vPvB assessment.

No information is available about the results of PBT and vPvB assessment of the product.

12.6 Endocrine disrupting properties.

This product doesn't contain components with environmental endocrine disrupting properties.

12.7 Other adverse effects.

The product is not affected by the Regulation (EC) No 1005/2009 of the European Parliament and of the Council of 16 September 2009 on substances that deplete the ozone layer.

No information is available about other adverse effects for the environment.

SECTION 13: DISPOSAL CONSIDERATIONS.

13.1 Waste treatment methods.

Do not dump into sewers or waterways. Waste and empty containers must be handled and eliminated according to current, local/national legislation.

Follow the provisions of Directive 2008/98/EC regarding waste management.

SECTION 14: TRANSPORT INFORMATION.

Transportation is not dangerous. In case of road accident causing the product's spillage, proceed in accordance with point 6.

-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 8 of 9
Print date: 27/01/2025

14.1 UN number or ID number.

Transportation is not dangerous.

14.2 UN proper shipping name.

Description:

ADR/RID: Not classified as hazardous for transport.

IMDG: Not classified as hazardous for transport.

ICAO/IATA: Not classified as hazardous for transport.

14.3 Transport hazard class(es).

Transportation is not dangerous.

14.4 Packing group.

Transportation is not dangerous.

14.5 Environmental hazards.

Transportation is not dangerous.

Transport by ship, FEm – Emergency sheets (F – Fire, S - Spills): Not applicable.

14.6 Special precautions for user.

Transportation is not dangerous.

14.7 Maritime transport in bulk according to IMO instruments.

Not classified as hazardous for transport.

SECTION 15: REGULATORY INFORMATION.

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture.

Volatile organic compound (VOC)

VOC content (p/p): 0 %

VOC content: 0 g/l

The product is not affected by Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products.

The product is not affected by the procedure established Regulation (EU) No 649/2012, concerning the export and import of dangerous chemicals.

15.2 Chemical safety assessment.

No Chemical Safety Assessment has been carried out for this substance/mixture by the supplier.

SECTION 16: OTHER INFORMATION.

Complete text of the H phrases that appear in section 3:

H315	Causes skin irritation.
H319	Causes serious eye irritation.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H335	May cause respiratory irritation.
H351	Suspected of causing cancer.
H373	May cause damage to organs through prolonged or repeated exposure.

Classification codes:

Carc. 2 : Carcinogen, Category 2

Eye Irrit. 2 : Eye irritation, Category 2

Resp. Sens. 1 : Respiratory sensitiser, Category 1

STOT RE 2 : Specific target organ toxicity following a repeated exposure, Category 2

-Continued on next page.-

SAFETY DATA SHEET

(in accordance with Regulation (EU) 2020/878)

MAXURETHANE INJECTION CONSOLIDATED CB

Version 1 Date of compilation: 27/01/2025



Page 9 of 9
Print date: 27/01/2025


STOT SE 3 : Specific target organ toxicity following a single exposure, Category 3
Skin Irrit. 2 : Skin irritant, Category 2

Classification and procedure used to derive the classification for mixtures according to Regulation (EC) 1272/2008 [CLP]:

Physical hazards	On basis of test data
Health hazards	Calculation method
Environmental hazards	Calculation method

It is advisable to carry out basic training with regard to health and safety at work in order to handle this product correctly.

Risk classification system NFPA 704:



Health hazard: 2 (Hazardous)
Flammability: 0 (Will not burn)
Reactivity: 0 (Stable)

Abbreviations and acronyms used:

CEN: European Committee for Standardization.
PPE: Personal protection equipment.

Key literature references and sources for data:

<http://eur-lex.europa.eu/homepage.html>
<http://echa.europa.eu/>
Regulation (EU) 2020/878.
Regulation (EC) No 1907/2006.
Regulation (EC) No 1272/2008.

The information given in this Safety Data Sheet has been drafted in accordance with COMMISSION REGULATION (EU) 2020/878 of 18 June 2020 amending Annex II to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemical substances and mixtures (REACH).

The information in this Safety Data Sheet on the Preparation is based on current knowledge and on current EC and national laws, as far as the working conditions of the users is beyond our knowledge and control. The product must not be used for purposes other than those that are specified without first having written instructions on how to handle. It is always the responsibility of the user to take the appropriate measures in order to comply with the requirements established by current legislation. The information contained in this Safety Sheet only states a description of the safety requirements for the preparation, and it must not be considered as a guarantee of its properties.